Evolution Research Group | Endeavor Clinical Trials

Research site

(Unclaimed)

Location

Physicians Plaza II 8042 Wurzbach #420, San Antonio, Texas, United States of America

Site insights

Top conditions

Top treatments

Acetaminophen

HTX-011

LY3841136

VX-548

Bupivacaine HCl

Ibuprofen

HSK3486

Propofol

Tirzepatide

Bupivacaine Hydrochloride

Parent organization

This site is a part of Evolution Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 104 total trials

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femor...

Enrolling

Osteoarthritis (OA) of the Knee

Drug: TPX-100 200mg, Once weekly for 4 weeks

Other: PBS

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

The principal aim of this study is to obtain safety and tolerability data when MRT-8102 is administered orally as single and multiple doses to health...

Enrolling

Healthy Volunteers

Elevated CRP

Drug: Placebo

Drug: MRT-8102

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling

Overweight

Obesity

Drug: LY3549492

Drug: LY3305677

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing...

Active, not recruiting

Analgesia

Drug: HTX-011

Drug: Acetaminophen

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses i...

Enrolling

Asthma

Drug: Placebo

Drug: AMG 691

New

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (ENLIGHTEN-6)

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity o...

Begins enrollment this month

Overweight

Obesity

Drug: Placebo

Drug: Eloralintide

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.Participation in Part A of th...

Enrolling

Overweight

Healthy

Drug: Placebo

Drug: LY4086940

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia (SOLARIS-1)

The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placeb...

Enrolling

Severe Hypertriglyceridemia

Drug: Placebo

Drug: Solbinsiran

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes (ZONE)

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabet...

Enrolling

Type 1 Diabetes Mellitus With Hypoglycemia

Drug: Placebo

Drug: ZT-01, 22 mg

A Study of TLC590 for Postsurgical Pain Following Bunionectomy

This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local i...

Enrolling

Postoperative Pain

Drug: Saline Placebo

Drug: Liposomal Bupivacaine

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: LY3549492

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: LY3841136

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a...

Enrolling

COVID-19

SARS-COV-2 Infection

Biological: Placebo

Biological: BNT162b2 Vaccine

Locations recently updated

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Enrolling

Hypertension

Cardiovascular Diseases

Drug: Placebo matching Vicadrostat

Drug: Vicadrostat

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (ENLIGHTEN-4)

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralint...

Not yet enrolling

Overweight or Obesity

Osteoarthritis

Drug: Placebo

Drug: Eloralintide

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The st...

Not yet enrolling

Obesity and Overweight

Drug: GZR18

Drug: Tirzepatide

Locations recently updated

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants (ROXI-ASPEN)

This study is researching an experimental drug called REGN7508 versus Acetylsalicylic Acid (ASA) (each called "study drug"). The study is focused on...

Enrolling

Symptomatic Venous Thromboembolism (VTE)

Drug: Placebo

Drug: Acetylsalicylic Acid (ASA)

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult particip...

Active, not recruiting

Anemia of Chronic Kidney Disease

Chronic Kidney Diseases

Drug: DISC-0974

Drug: Placebo

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg